KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.32
+1.89%Margins
Gross margin
94.7%
EBITDA margin
-562.8%
EBIT margin
-675.8%
Net margin
-553.9%
FCF margin
-322.9%
-31.7%
Return on equity
-28.9%
Return on assets
-36.5%
Return on invested capital
0.05x
Asset turnover
-$48.0M
Cash from operations
$13
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026